Natural Management

Evidence-based natural approaches to managing Raynaud's syndrome — omega-3 fatty acids, pine bark extract (Pycnogenol), Ginkgo biloba, L-arginine for nitric oxide support, and lifestyle strategies to reduce cold-triggered vasospasm

Raynaud's syndrome causes the small arteries in the fingers — and sometimes toes, ears, and nose — to go into sudden spasm when triggered by cold temperatures or emotional stress, cutting off circulation and producing the characteristic colour changes: white (blanching), then blue (cyanosis), then red (reactive hyperaemia) as blood flow returns. It affects roughly 3–5% of the general population, predominantly women, and can range from a mild inconvenience to a debilitating problem in cold climates. Most cases are primary — no underlying disease — but secondary Raynaud's occurs alongside autoimmune conditions including scleroderma and lupus, and tends to be more severe. Natural approaches targeting the underlying vascular mechanisms — improving nitric oxide availability, reducing excessive vasoconstriction, and supporting microcirculation — can meaningfully reduce attack frequency and severity, particularly in primary cases. Pine bark extract (Pycnogenol) raised the lowest recorded finger temperature by 30% in a controlled study [1], Ginkgo biloba reduced weekly attack frequency by 56% in a double-blind trial [2], and omega-3 fish oil supplementation prevented laboratory-induced vasospasm in 45% of primary Raynaud's patients who were previously susceptible [3].

What Goes Wrong in Raynaud's

Normal circulation responds to cold by modestly constricting superficial blood vessels to conserve body heat. In Raynaud's, this response is dramatically exaggerated: the arterioles (tiny arteries) in the digits go into full spasm, collapsing blood flow almost entirely. The three-phase colour response reflects what's happening physiologically:

White (pallor): Arterial spasm cuts off inflow — fingers turn chalk-white and cold
Blue (cyanosis): Residual blood in the capillaries loses oxygen — the digits turn bluish or purple
Red (hyperaemia): Vasospasm releases and blood rushes back — flushing, burning, and throbbing as circulation is restored

Several abnormalities drive this exaggerated response:

Nitric oxide (NO) deficiency. The endothelial cells lining blood vessel walls normally produce nitric oxide, which relaxes smooth muscle and keeps vessels dilated. In Raynaud's patients, endothelial NO production is reduced — partly due to elevated levels of asymmetric dimethylarginine (ADMA), a naturally occurring molecule that competes with L-arginine (the amino acid substrate for NO synthesis) and blocks its conversion. [4] This ADMA/arginine imbalance means vessels lose the vasodilatory tone that should counteract cold-induced constriction.

Overactive alpha-2 adrenergic receptors. The sympathetic nervous system constricts blood vessels via alpha-2 adrenergic receptors on smooth muscle cells. In primary Raynaud's, these receptors are abnormally numerous or sensitive, particularly when skin temperature drops — creating a positive feedback loop where cooling both triggers sympathetic activation and increases receptor sensitivity.

Endothelin excess. Endothelin-1 is one of the most potent vasoconstrictors in the body, produced by endothelial cells under stress. Raynaud's patients tend to have elevated circulating endothelin-1, particularly during attacks.

Secondary Raynaud's (associated with connective tissue disease) involves the same mechanisms but with additional structural changes: vessel wall thickening, capillary dropout visible on nailfold capillaroscopy, and in scleroderma, progressive fibrosis of vessel walls that can cause ischaemic digital ulcers if left unmanaged.

Identifying and Avoiding Triggers

Cold is the most common trigger, but the threshold varies considerably between people. Some experience attacks only in freezing temperatures; others are triggered by handling cold items from a refrigerator, air conditioning, or even holding a cold drink. Common modifiable triggers:

Cold air or cold objects — the most universal trigger; even brief exposure to refrigerator items can provoke an attack
Emotional stress — sympathetic nervous system activation mimics cold by releasing norepinephrine and triggering alpha-2 receptor-mediated vasoconstriction
Caffeine and nicotine — both cause vasoconstriction; smoking is particularly strongly associated with worse Raynaud's and should be stopped completely
Vibrating tools — prolonged use of vibrating equipment (chainsaws, jackhammers, power drills) can cause occupational Raynaud's and is a distinct management challenge
Certain medications — beta-blockers (used for blood pressure and heart conditions), migraine drugs containing ergotamine, and some chemotherapy agents (bleomycin, vinblastine) can precipitate or worsen attacks; discuss alternatives with a prescribing physician

Practical cold-weather strategies:

Keep the core warm, not just the extremities — cold hands are often a downstream consequence of peripheral vasoconstriction triggered to protect core temperature. Layered insulating clothing on the torso, neck, and head is as important as wearing gloves. Start warming up before going outside rather than reacting to an attack. Chemical hand warmers, heated gloves with battery packs, and steering wheel covers are useful tools. Avoid going from a warm room directly into cold air without transition time.

Pine Bark Extract (Pycnogenol)

Pycnogenol is a proprietary extract of French maritime pine bark (Pinus pinaster) standardised to contain oligomeric proanthocyanidins (OPCs), bioflavonoids, and phenolic acids. It improves microcirculation through several relevant mechanisms: stimulating endothelial NO synthesis, reducing endothelin-1 production, inhibiting thromboxane-mediated platelet aggregation (which can impede small-vessel blood flow), and reducing oxidative stress that degrades nitric oxide.

A 4-week prospective registry study enrolled 67 women aged 30–40 with mild primary Raynaud's syndrome who were all employed in refrigerated shop environments. Participants received either standard management alone (N=33) or standard management plus Pycnogenol 100 mg/day (N=34). The Pycnogenol group showed a 30% improvement in lowest recorded finger temperature (from 20.3°C to 26.4°C) compared to only 12.7% improvement in controls (from 20.5°C to 23.1°C; p<0.05). Coldness, burning pain, paraesthesias, and irregular colour changes all improved more significantly with Pycnogenol. Transcutaneous oxygen pressure — a measure of microvascular oxygen delivery — also increased significantly, and oxidative stress markers decreased. Only 1 of 34 Pycnogenol patients (3%) required escalation to drug treatment, versus 5 of 33 controls (15%). [1]

Practical guidance: The studied dose is 100 mg/day. Pycnogenol is well-tolerated; side effects are uncommon and typically mild (mild digestive discomfort). Effects on Raynaud's symptoms typically emerge over 2–4 weeks of consistent use.

Ginkgo Biloba

Ginkgo biloba improves peripheral circulation primarily through prostacyclin-mediated vasodilation, platelet-activating factor (PAF) inhibition (PAF promotes platelet aggregation and vasoconstriction), and inhibition of thromboxane B2. These mechanisms are particularly relevant to the small-vessel pathology of Raynaud's.

A randomised, double-blind, placebo-controlled trial enrolled 22 patients with primary Raynaud's syndrome and allocated them to either Ginkgo biloba phytosome extract (equivalent to 360 mg Ginkgo biloba extract daily in divided doses) or placebo for 10 weeks. The Ginkgo group experienced a significant reduction in attack frequency: from 13.2 attacks/week at baseline to 5.8 attacks/week at 10 weeks (a 56% reduction). The placebo group reduced from 12.3 to 9.0 attacks/week (27% reduction). The difference between groups was statistically significant (p<0.05), and Ginkgo was well-tolerated with no significant adverse events. [2]

Ginkgo has known antiplatelet effects and should not be combined with blood-thinning medications (warfarin, clopidogrel, aspirin at higher doses) without medical supervision.

Omega-3 Fatty Acids and Diet

Omega-3 fatty acids EPA and DHA from fish oil have direct effects on vascular smooth muscle function: they shift prostaglandin synthesis toward the vasodilatory, anti-aggregatory PGI3-series prostaglandins, reduce thromboxane A2 (which constricts vessels and promotes platelet aggregation), and improve the deformability of red blood cells — making them better able to navigate the narrow, spasming capillaries during a Raynaud's attack.

A double-blind, placebo-controlled trial studied 32 patients with primary or secondary Raynaud's who consumed either high-dose fish oil (providing approximately 4g EPA + 2.6g DHA daily, via 12 capsules) or olive oil placebo for 12–17 weeks. In primary Raynaud's, fish oil significantly delayed or prevented cold-induced vasospasm: 5 of 11 fish-oil patients (45.5%) who had a positive provocation test at baseline could not be induced to develop attacks by 6–12 weeks, compared with only 1 of 9 controls (11%). The effect was not seen in secondary Raynaud's, consistent with the more structurally complex vascular pathology in that group. [3]

Dietary context: The pro-inflammatory omega-6 landscape of the Western diet (high linoleic acid from seed oils — soybean, corn, sunflower) competes with omega-3 metabolism and promotes a prostaglandin profile that worsens vascular reactivity. Reducing seed oil consumption and replacing with olive oil, avocado oil, or butter as primary cooking fats shifts the prostaglandin balance in a beneficial direction. Aim for oily fish (sardines, mackerel, wild salmon, herring) at least 3 times per week and consider a concentrated triglyceride-form EPA+DHA supplement providing at least 2–3g combined daily. See our Omega-3 page for more on forms and dosing.

L-Arginine and Nitric Oxide Support

Since nitric oxide deficiency is central to the vascular dysfunction in Raynaud's, supplementing with L-arginine — the amino acid substrate for NO synthesis — has a biological rationale. The problem is not a simple deficiency of arginine itself, but rather elevated ADMA (asymmetric dimethylarginine) that competes with arginine at the enzyme nitric oxide synthase (eNOS). ADMA levels are elevated in both primary and secondary Raynaud's and correlate with disease severity.

A 2019 review of the clinical evidence for L-arginine in secondary Raynaud's (where NO deficiency is well-established) found that intra-arterial L-arginine infusions significantly decreased the vasospastic response to cold provocation, and that increasing serum L-arginine levels is an effective treatment strategy in cases where ADMA-to-arginine ratio is elevated. Case reports have documented digital ulcer healing with oral L-arginine supplementation. [4] Oral supplementation (typically 2–6g/day) has shown benefit in several small studies and in practice appears most useful in secondary Raynaud's, where endothelial NO deficiency is more pronounced.

Other dietary strategies that support NO production include:

Dietary nitrates: Beetroot, arugula (rocket), leafy greens, and celery are rich in inorganic nitrates that are converted to nitric oxide via the entero-salivary nitrate-nitrite-NO pathway
Polyphenols: Quercetin, epicatechin (in dark chocolate and berries), and resveratrol all stimulate eNOS activity
Reducing ADMA naturally: Exercise, folate, and EGCG from green tea all reduce circulating ADMA levels
Vitamin C and E: Both scavenge reactive oxygen species that destroy NO, effectively extending its bioavailability in vessel walls

Exercise and Endothelial Health

Regular aerobic exercise is one of the most effective strategies for improving endothelial function and increasing baseline NO production. Exercise causes repeated mechanical shear stress on vessel walls, which upregulates eNOS expression and increases the endothelium's capacity for NO synthesis. This improved endothelial function provides greater vasodilatory reserve — making the vessels less likely to collapse completely during a cold or stress trigger.

Even 20–30 minutes of moderate aerobic exercise (brisk walking, cycling, swimming) 4–5 days per week produces measurable improvements in endothelial function within 6–8 weeks. Indoor exercise or exercise in properly heated environments is obviously preferable for Raynaud's sufferers. See our Zone 2 Cardio page for guidance on exercising at the intensity that best supports cardiovascular health.

Mind-Body and Stress Management

Psychological stress triggers Raynaud's attacks through the same sympathetic pathway as cold — norepinephrine release activates alpha-2 adrenergic receptors on digital arterioles, causing vasoconstriction. Stress management is therefore a direct physiological intervention, not merely a general wellness suggestion.

The major evidence-based stress reduction approaches with relevance to Raynaud's:

Thermal biofeedback: Patients are taught to raise their own finger temperature voluntarily through visual or auditory feedback. Multiple controlled studies have demonstrated that trained individuals can increase digital skin temperature by 3–5°C during cold exposure, effectively preventing attacks. This approach requires structured training sessions with a biofeedback therapist but produces lasting changes in autonomic control.

Mindfulness-based stress reduction (MBSR): Reduces baseline sympathetic tone and attenuates the vascular response to psychological stressors. Particularly useful for people whose Raynaud's is predominantly stress-triggered.

Magnesium: Magnesium has calcium channel-blocking properties in smooth muscle and reduces sympathetic nervous system reactivity. Magnesium deficiency increases vascular smooth muscle tone and is associated with increased sensitivity to vasoconstriction. Supplementation (200–400 mg/day magnesium glycinate or malate) is a low-risk adjunct that also supports sleep quality and stress resilience. See our Magnesium page.

Breathwork: Slow diaphragmatic breathing (4–6 breaths/minute) activates the parasympathetic nervous system, countering the sympathetic drive that precipitates attacks. See our Meditation and Breathwork page for practical techniques.

Secondary Raynaud's: Additional Considerations

Secondary Raynaud's is associated with serious systemic diseases — scleroderma, mixed connective tissue disease, lupus, Sjögren's syndrome, rheumatoid arthritis — and requires medical monitoring regardless of natural treatment approaches. Digital ulcers, worsening attacks, or asymmetric attacks (affecting one hand disproportionately) warrant urgent medical evaluation to rule out underlying pathology.

For people with secondary Raynaud's, the natural interventions above remain supportive but pharmaceutical treatment (typically calcium channel blockers such as nifedipine, or phosphodiesterase-5 inhibitors in severe cases) is often required. Natural and pharmaceutical approaches are not mutually exclusive — improving underlying endothelial function, reducing inflammation (see our Autoimmune Support page), and optimising omega-3 status all remain valuable adjuncts to drug therapy.

Evidence Review

Pycnogenol Registry Study (PMID: 31637898)

Hu et al. conducted a 4-week prospective registry study comparing standard management (SM) alone versus SM plus Pycnogenol supplementation (100 mg/day) in 67 women with mild primary Raynaud syndrome employed in refrigerated retail environments. All participants were aged 30–40, had symmetrical vasospastic changes affecting both hands, and were experiencing at least 8 attacks per week at baseline. The primary outcome was change in lowest measured finger temperature assessed by thermography. At 4 weeks, the Pycnogenol group showed a +30.04% improvement in lowest finger temperature (from 20.3°C to 26.4°C) compared with +12.7% in controls (from 20.5°C to 23.1°C; p<0.05). Secondary outcomes — coldness, burning pain, paraesthesias, and irregular colour changes — all improved significantly more in the Pycnogenol group (p<0.05). Transcutaneous oxygen pressure, measuring microvascular oxygen delivery, increased more with Pycnogenol, and plasma markers of oxidative stress (malondialdehyde) decreased more in the treated group. The proportion requiring escalation to prostaglandin E1 drug treatment was 2.94% in the Pycnogenol group versus 15.15% in controls. Limitations include the non-randomised registry design and the all-female, occupationally-defined study population — the findings need replication in a fully randomised controlled trial with a broader population. The biological plausibility is strong given Pycnogenol's documented effects on eNOS stimulation, endothelin-1 reduction, and OPC-mediated microvascular improvement.

Ginkgo Biloba RCT (PMID: 12710841)

Muir, Robb, McLaren, Daly, and Belch conducted a 10-week randomised double-blind placebo-controlled trial of Ginkgo biloba phytosome extract versus placebo in 22 patients with primary Raynaud's syndrome at the University of Dundee, UK. Patients were randomly allocated to either Ginkgo biloba standardised extract (providing the equivalent of 360 mg extract daily) or identical placebo capsules, with a 2-week washout and crossover design. The primary outcome was self-reported attack frequency recorded via diary. Ginkgo biloba reduced attacks from a mean 13.2/week at baseline to 5.8/week at 10 weeks (56% reduction) compared with a reduction from 12.3 to 9.0/week with placebo (27% reduction); the between-group difference was statistically significant (p<0.05). Tolerability was excellent, with no significant adverse events in either group. The crossover design strengthened statistical power given the small sample. The mechanism is attributed to Ginkgo's inhibition of platelet-activating factor (PAF) and thromboxane B2, and stimulation of prostacyclin synthesis — all of which reduce abnormal platelet aggregation and vasoconstriction in digital arterioles. The trial's small size and absence of an objective vascular endpoint (such as thermography or finger photoplethysmography) are limitations. A 2009 meta-analysis [5] identified this trial as one of the more methodologically sound complementary medicine RCTs in Raynaud's but called for larger, longer trials.

Fish Oil RCT (PMID: 2536517)

DiGiacomo, Kremer, and Shah conducted a double-blind, placebo-controlled, prospective study of dietary fish oil supplementation in 32 patients with primary (N=20) or secondary Raynaud's phenomenon (N=12) at Albany Medical College. Participants ingested 12 fish-oil capsules daily (providing 3.96g EPA and 2.64g DHA) or 12 olive-oil placebo capsules for 17 weeks. The primary outcome was susceptibility to laboratory-provoked vasospasm during a standardised cold-water immersion challenge, assessed with finger strain gauge plethysmography at baseline and weeks 6, 12, and 17. In primary Raynaud's patients, fish oil significantly improved cold tolerance: 5 of 11 fish-oil patients (45.5%) who had a positive provocation test at baseline could not be induced to develop vasospasm at 6 or 12 weeks versus only 1 of 9 olive-oil controls (11%; p=0.05). Digital blood pressure at 10°C cold challenge improved significantly in primary RP with fish oil (+36 mmHg vs +7 mmHg). No significant benefit was found in secondary Raynaud's — consistent with the structural vessel wall damage in scleroderma and related conditions that cannot be reversed by prostaglandin modulation alone. The high capsule burden (12/day) in this trial reflects the dose requirements; modern concentrated omega-3 formulations can deliver equivalent EPA+DHA in 2–4 capsules. The olive oil comparator was not wholly inert (oleocanthal in olive oil has anti-inflammatory activity) which would bias toward the null, suggesting the true effect of fish oil may be somewhat larger than reported.

L-Arginine and ADMA Review (PMID: 30004597)

Curtiss, Schwager, Lo Sicco, and Franks conducted a systematic review of clinical and mechanistic evidence for L-arginine and asymmetric dimethylarginine (ADMA) in secondary Raynaud's phenomenon, published in the Journal of the European Academy of Dermatology and Venereology. The review established that endothelial dysfunction — specifically impaired nitric oxide synthesis — is a central pathophysiological mechanism in secondary Raynaud's, driven by elevated ADMA that competitively inhibits eNOS. Trials included showed that intra-arterial L-arginine infusions significantly reduced the cold-induced vasospastic response, and that intra-arterial sodium nitroprusside (a direct NO donor) produced similar vasodilation — confirming NO insufficiency as the proximate cause. Case reports documented digital ulcer healing in severe secondary RP with high-dose oral L-arginine (8g/day). A pharmacokinetic consideration is that oral L-arginine is substantially metabolised by intestinal arginase before reaching systemic circulation, meaning that oral doses need to be higher (typically 3–8g/day in divided doses) to achieve meaningful increases in plasma arginine. The review noted that L-citrulline, which bypasses intestinal arginase and is efficiently converted to L-arginine in the kidneys, may be more effective than L-arginine itself for raising plasma arginine and NO production — though this has not been directly tested in Raynaud's. See our L-Arginine page for more on the arginine-citrulline cycle.

CAM Meta-Analysis (PMID: 19433434)

Malenfant, Catton, and Pope conducted a literature review and meta-analysis of complementary and alternative medicine interventions for Raynaud's phenomenon, published in Rheumatology (Oxford) in 2009. The analysis identified 13 eligible randomised controlled trials across multiple interventions: essential fatty acids (fish oil and evening primrose oil), Ginkgo biloba, vitamin C, topical nitrates (nitroglycerin), acupuncture, and biofeedback. Pooled analysis was possible only for biofeedback and found that thermal biofeedback produced moderate improvements in attack frequency and severity. For fish oil and Ginkgo, the analysis noted the same individual trials reviewed here, and concluded that — while promising — the evidence base was limited by small sample sizes, heterogeneous outcome measures, and lack of standardised cold provocation protocols across studies. The authors called for larger, better-designed trials with standardised thermographic endpoints. Despite the limitations, the overall direction of the evidence across all reviewed interventions was consistently positive, and the review supported the use of lifestyle and supplemental interventions as reasonable additions to conventional management in mild-to-moderate primary Raynaud's, particularly given the favourable safety profile compared to pharmaceutical vasodilators. The 2019 Pycnogenol registry study [1] and the 2019 L-arginine review [4] both post-date this meta-analysis and represent the most recent additions to the evidence base for natural approaches.

References

Management of mild, primary Raynaud Syndrome: supplementation with Pycnogenol®Hu S, Hosoi M, Belcaro G, Dugall M, Feragalli B, Togni S, Riva A. Minerva Cardioangiologica, 2019. PubMed 31637898 →
The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trialMuir AH, Robb R, McLaren M, Daly F, Belch JJ. Vascular Medicine, 2002. PubMed 12710841 →
Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective studyDiGiacomo RA, Kremer JM, Shah DM. The American Journal of Medicine, 1989. PubMed 2536517 →
The clinical effects of L-arginine and asymmetric dimethylarginine: implications for treatment in secondary Raynaud's phenomenonCurtiss P, Schwager Z, Lo Sicco K, Franks AG Jr. Journal of the European Academy of Dermatology and Venereology, 2019. PubMed 30004597 →
The efficacy of complementary and alternative medicine in the treatment of Raynaud's phenomenon: a literature review and meta-analysisMalenfant D, Catton M, Pope JE. Rheumatology, 2009. PubMed 19433434 →